Pharsight

Natazia is owned by Bayer Hlthcare.

Natazia contains Dienogest; Estradiol Valerate.

Natazia has a total of 2 drug patents out of which 0 drug patents have expired.

Natazia was authorised for market use on 06 May, 2010.

Natazia is available in tablet;oral dosage forms.

Natazia can be used as prevention of pregnancy, treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception.

The generics of Natazia are possible to be released after 30 January, 2028.

Application	Filing Date	Opposition Party	Legal Status
EP05730867A	2011-04-13	Lupin Limited	Patent maintained as amended
EP05730867A	2011-04-12	Laboratorios Léon Farma, S.A.	Patent maintained as amended
EP05022324A	2009-11-26	Sandoz International GmbH	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071577	BAYER HLTHCARE	Multi-phase contraceptive preparation based on a natural estrogen	May, 2026 (2 years from now)
US8153616	BAYER HLTHCARE	Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same	Jan, 2028 (4 years from now)

Do you want to check out NATAZIA patents from before 2022?

Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient

Market Authorisation Date: 06 May, 2010

Treatment: Prevention of pregnancy; Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception

Dosage: TABLET;ORAL